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Abstract
Background: Alphaviruses can cause fatal encephalitis in humans. Natural infections occur via the bite of infected
mosquitos, but aerosol transmissibility makes some of these viruses potential bioterrorism agents. Central nervous
system (CNS) host responses contribute to alphavirus pathogenesis in experimental models and are logical therapeutic
targets. We investigated whether reactive oxygen species (ROS) generated by nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase (Nox) activity within the CNS contributes to fatal alphavirus encephalitis in mice.
Methods: Infected animals were treated systemically with the angiotensin receptor-blocking drug, telmisartan, given
its ability to cross the blood-brain barrier, selectively block type-1 angiotensin receptors (AT1R), and inhibit Nox-derived
ROS production in vascular smooth muscle and other extraneural tissues. Clinical, virological, biochemical, and
histopathological outcomes were followed over time.
Results: The importance of the angiotensin II (Ang II)/AT1R axis in disease pathogenesis was confirmed by
demonstrating increased Ang II levels in the CNS following infection, enhanced disease survival when CNS Ang II
production was suppressed, increased AT1R expression on microglia and tissue-infiltrating myeloid cells, and enhanced
disease survival in AT1R-deficient mice compared to wild-type (WT) controls. Systemic administration of telmisartan
protected WT mice from lethal encephalitis caused by two different alphaviruses in a dose-dependent manner without
altering virus replication or exerting any anti-inflammatory effects in the CNS. Infection triggered up-regulation of
multiple Nox subunits in the CNS, while drug treatment inhibited local Nox activity, ROS production, and oxidative
neuronal damage. Telmisartan proved ineffective in Nox-deficient mice, demonstrating that this enzyme is its main
target in this experimental setting.
Conclusions: Nox-derived ROS, likely arising from CNS myeloid cells triggered by AT1R signaling, are pathogenic
during fatal alphavirus encephalitis in mice. Systemically administered telmisartan at non-hypotensive doses targets
Nox activity in the CNS to exert a neuroprotective effect. Disruption of this pathway may have broader implications for
the treatment of related infections as well as for other CNS diseases driven by oxidative injury.
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encephalitis, Nox, Oxidative injury
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Background
Alphaviruses cause acute and sometimes fatal encephalo-
myelitis in humans. Most infections are spread via
infected mosquito vectors, although some can be trans-
mitted as aerosols making them potential bioterrorism
agents [1]. The intentional release of an alphavirus amidst
a large population center is a public health concern be-
cause antiviral agents effective against these pathogens are
not available. One alphavirus, neuroadapted Sindbis virus
(NSV), causes fatal encephalomyelitis in mice and closely
reproduces many features of neurotropic alphavirus infec-
tions in humans [2, 3]. Like other alphaviruses, NSV tar-
gets neurons of the brain and spinal cord without causing
direct infection of glial cells [3, 4]. The fate of neurons
then determines disease outcome [5]. Not only does NSV
cause direct virus-induced neuronal cell death [5], but
substantial bystander injury to uninfected neurons also oc-
curs [6, 7]. This bystander injury suggests that host re-
sponses contribute to alphavirus pathogenesis [8, 9], and
recent investigations show that therapies targeting innate
immune responses in the central nervous system (CNS)
can protect infected hosts without altering virus tropism,
replication, or clearance [7, 10, 11]. Microglia and astro-
cytes are both implicated in this bystander injury [11–14],
but the molecular pathways through which innate host re-
sponses lead to neuronal injury during CNS alphavirus in-
fections remain incompletely understood.
Among the numerous host responses known to promote
neuronal injury in the CNS are reactive oxygen species
(ROS) generated by activation of the nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase (Nox) enzyme
complex [15, 16]. Indeed, aberrant activation of Nox in
microglial cells is now implicated in a variety of neurode-
generative disease models [17–20]. The contributions of
Nox-derived ROS generated as part of the host response to
CNS viral infection are less clear; on one hand, these ROS
may directly damage virus particles or lower the permis-
siveness of cells for virus replication, while on the other,
their generation as a part of the respiratory burst by innate
immune cells can produce significant collateral tissue dam-
age [21]. A growing body of histochemical data show that
oxidative neuronal injury occurs with CNS viral infections
[21], suggesting that blockade of Nox activation could have
therapeutic benefits in these diseases.
The vasoconstricting effects of angiotensin II (Ang II)
on peripheral blood vessels occur via Nox-mediated pro-
duction of superoxide anions by vascular smooth muscle
cells [22, 23]. As a result, selective non-peptide antago-
nists of type-1 angiotensin II receptors (AT1R) that po-
tently inhibit Nox activation have been developed as
anti-hypertensive therapies for humans. More recently,
several angiotensin II receptor blockers (ARB) have been
shown to exert neuroprotective effects in animal disease
models [24–27]. One ARB, telmisartan, is highly blood-
brain barrier (BBB) penetrant and produces near
complete and sustained blockade of AT1R without af-
fecting type-2 angiotensin II receptor (AT2R) signaling
[28]. Given the expanding use of ARB to suppress Nox-
mediated ROS production in other non-vascular tissues
[29], we considered telmisartan a useful reagent to test
the hypothesis that Nox-mediated ROS production
within the CNS is an important pathogenic event during
experimental alphavirus encephalitis in mice. Our data
show that systemically administered telmisartan blocks
CNS Nox activity and ROS production induced by NSV
infection, protects infected hosts, and suppresses oxida-
tive neuronal damage. These findings suggest a broader
potential applicability of ARB to target Nox activity in
the setting of infectious, inflammatory, and even degen-
erative disorders of the human CNS.
Methods
Animals
Inbred C57BL/6 mice, mice heterozygous for deficien-
cies of the individual Nox subunits, p47phox or gp91phox,
both bred on a C57BL/6 background, mice expressing
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green fluorescent protein (GFP) in one allele of the
CX3C chemokine receptor-1 (CX3CR1 or fractalkine re-
ceptor) bred on a C57BL/6 background (hereafter re-
ferred to as CX3CR1GFP/+ mice) and mice deficient in
AT1R bred on a C57BL/6 background (hereafter referred
to as AT1R knockout (KO) mice) were all obtained from
Jackson Laboratories (Bar Harbor, ME). Double KO
gp91phox/p47phox mice (hereafter referred to as gp91/p47
double knockout (DKO) mice) were generated de novo
and bred on site. Animals were housed under specific
pathogen-free, barrier facility conditions on a 10-h/14-h
light/dark cycle with food and water available ad libitum.
All animal procedures were completed using isoflurane
anesthesia (Abbott Laboratories, Chicago, IL). All animal
experiments, including those incorporating paralysis or
death as study endpoints, were conducted in strict ac-
cordance with protocols approved by the University of
Michigan Committee on Use and Care of Animals as
well as with federal guidelines.
Induction of NSV encephalomyelitis and NSV-related
animal manipulations
NSV viral stocks were grown and assayed for plaque for-
mation on BHK-21 cells. Stock titers of 107 plaque-
forming units (pfu)/ml were stored at −80 °C until use. To
induce encephalomyelitis, mice were injected with
1000 pfu of NSV or NSV-GFP suspended in 20 μl of
phosphate-buffered saline (PBS) directly into the right
cerebral hemisphere. For those experiments where tissue
samples were not being collected for ex vivo analyses, each
infected animal was scored by a blinded examiner into
one of the following groups: (1) normal or minimally af-
fected, (2) mild paralysis (some weakness of one or both
hind limbs), (3) moderate paralysis (weakness of one hind
limb, paralysis of the other hind limb), (4) severe paralysis
(complete paralysis of both hind limbs), or (5) moribund/
dead. Moribund mice were euthanized immediately and
were considered to have died the following day for all stat-
istical comparisons, as prior studies demonstrated that all
animals reaching this disease stage never survived more
than another 24 h [7, 10, 13]. Animals also received intra-
peritoneal (i.p.) injections of telmisartan (Sigma-Aldrich,
St. Louis, MO) or a vehicle control twice daily in a volume
of 200 μl of 0.9 % sodium chloride solution, pH 9.0. Such
an alkalinized diluent was both necessary for and capable
of maintaining full drug solubility. Doses up to 100 mg/
kg/day were administered starting 12 h after viral chal-
lenge. Other mice received twice daily i.p. injections of
captopril (10 mg/kg/day, Sigma-Aldrich) suspended in
200 μl of PBS or a PBS vehicle control. All of these experi-
ments were conducted in strict accordance with protocol
# PRO00005049 approved by the University of Michigan
Committee on Use and Care of Animals.
At predetermined disease stages, some mice were eu-
thanized via transcardiac perfusion with PBS under
anesthesia. For animals where in vivo labeling of ROS
production was desired, mice were first injected i.p. with
50 mg/kg dihydroethidium (DHE, Sigma-Aldrich) 1 h
prior to perfusion. For all tissue enzyme immunoassays
(EIA), bead-based multi-analyte cytokine and chemokine
assays, Western blots, flow cytometry-based sorting of
immune cell subsets, virus titration assays, and biochem-
ical assays of tissue superoxide production, brains and
spinal cords were quickly dissected for further process-
ing. For immunohistochemical and immunofluorescence
studies, animals were perfused a second time with
chilled PBS containing 4 % paraformaldehyde (PFA) be-
fore dissection.
Induction of western equine encephalitis virus
encephalitis
The Cba 87 strain of western equine encephalitis virus
(WEEV) was generated from the complementary DNA
(cDNA) clone pWE2000 as previously described [30, 31].
A low passage stock of infectious virus generated in Vero
cells was expanded twice in C6/36 mosquito cells to pro-
duce viral stocks containing 107 pfu/ml. All virus aliquots
were stored at −80 °C until use. Experiments using infec-
tious WEEV were conducted in an animal-compatible,
federally certified biosafety level 3 (BSL3) containment fa-
cility in strict accordance with standard operating proce-
dures and protocols approved by both the University of
Michigan Institutional Biosafety Committee and the Uni-
versity of Michigan Committee on Use and Care of
Animals (animal protocol # PRO00005204). Mice were
housed in our animal BSL3 facility on a 10-h/14-h light/
dark cycle with food and water available ad libitum.
For WEEV infections, recipient mice were inoculated
subcutaneously with 104 pfu of Cba 87 suspended in a
total volume of 50 μl of PBS. Cohorts of infected mice
were weighed and scored daily using a clinical rating
scale previously established for WEEV infection: 0, nor-
mal; 1, slightly ruffled fur, no visible signs of infection; 2,
very ruffled fur, definite signs of infection with reduced
cage activity; 3, very ruffled fur, hunched posture, re-
duced mobility; 4, very ruffled fur, hunched posture, lit-
tle to no mobility, rapid breathing (moribund); and 5,
dead [32]. All animals also received i.p. injections of tel-
misartan (Sigma-Aldrich) or a vehicle control twice daily
in a total volume of 200 μl of 0.9 % sodium chloride so-
lution, pH 9.0, at a dose of 100 mg/kg/day starting 12 h
after viral challenge. Animals reaching a disease score of
4 were euthanized immediately and were considered to
have died the following day for all statistical compari-
sons, as prior disease progression studies demonstrated
that moribund mice never survived more than an
additional 24 h [32].
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Measurement of Ang II levels and cytokine and
chemokine concentrations in tissue extracts
Control and NSV-infected mice were perfused with PBS,
and brains and spinal cords extracted, snap-frozen on
dry ice, and stored at −80 °C until use. Thawed tissues
were minced and homogenized in 0.5 ml of PBS con-
taining a protease inhibitor cocktail (Roche Life Science,
Indianapolis, IN). Homogenates were centrifuged to pel-
let all remaining tissue debris. The total protein content
in each tissue supernatant was measured using the
Pierce Coomassie Protein Assay Reagent (Thermo Fisher
Scientific, Rockford, IL). Ang II levels were measured in
each sample using a commercially available EIA kit
(Cayman Chemical Company, Ann Arbor, MI). The re-
sults presented reflect pg Ang II/mg of total protein ex-
tracted from tissue of four to six animals at each time
point examined. The Milliplex mouse cytokine detection
system (EMD Millipore, Billerica, MA) was used accord-
ing to the manufacturer’s instructions to quantify cyto-
kine and chemokine levels directly in tissue extracts.
Plates were read on a Luminex 200 instrument (EMD
Millipore), and cytokine and chemokine concentrations
(pg/ml) calculated by the BioPlex manager software
(Bio-Rad, Hercules, CA) using standard curves. Results
presented reflect the mean ± standard error of the mean
(SEM) of cytokine or chemokine quantities per milliliter
of plasma or per milligram of total extracted tissue pro-
tein from five animals at each time point. The lower
limit of detection for these assays was 1.6 pg/ml.
Tissue Western blots
Brains and spinal cords were homogenized in a tissue lysis
buffer (10 mM Tris, 1 % sodium dodecyl sulfate (SDS),
1 mM sodium orthovandate, pH 7.6) supplemented with a
commercial protease inhibitor cocktail (Roche Life Sci-
ence). Lysates were centrifuged to remove undigested tissue
debris and the total protein concentration of each super-
natant was determined using the Pierce Coomassie Protein
Assay Reagent (Thermo Fisher Scientific). Samples were
boiled in 4× protein sample buffer and 20 μg/well run on
SDS-polyacrylamide gels. Proteins were transferred to
PVDF membranes and blocked overnight at 4 °C in a 5 %
non-fat skim milk solution in Tris-buffered saline (TBS)
containing 0.5 % Tween 20. Membranes were then incu-
bated with one of the following primary antibodies:
polyclonal goat anti-AT1R (1:500, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), polyclonal rabbit anti-gp91 (1:1000,
Abcam, Cambridge, MA), or polyclonal rabbit anti-p47
(1:500, EMD Millipore) for 1 h at room temperature. All
primary antibodies were raised against synthetic peptides
derived from the corresponding human gene sequence,
and both cross-reactivity and specificity with the corre-
sponding mouse protein previously established [33–35].
Following five washes, membranes were then incubated
with either rabbit anti-goat horseradish peroxidase (HRP)-
conjugated secondary antibody or goat anti-rabbit HRP-
conjugated secondary antibody (both used at 1:10,000,
EMD Millipore) for 1 h at room temperature. Membranes
were washed five times again, and the HRP signal detected
using ECL Western blotting detection reagent (GE
Healthcare Life Sciences, Pittsburgh, PA) on X-ray film.
Membranes were then stripped using Western blot strip-
ping buffer (Thermo Fisher Scientific) and relabeled with
β-actin loading control antibody (1:5000, Thermo Fisher
Scientific) using the same steps described above. Once all
the β-actin signals were obtained, all band densities were
quantified using the ImageJ software package (NIH, Be-
thesda, MD). The band density for each protein was first
normalized to the β-actin signal detected in the same lane,
and the mean of the uninfected samples were then set to
an arbitrary expression level of 1.0. Relative protein ex-
pression across the full course of acute NSV infection was
determined compared to uninfected controls, and relative
expression in five samples at each disease stage was ana-
lyzed for statistical significance.
Tissue staining and imaging procedures
Unless otherwise specified, all tissues used for histo-
logical studies were post-fixed for 6 h in 4 % PFA in
PBS, cryopreserved overnight in 30 % sucrose in PBS,
and snap-frozen in CRYO-OCT Compound (Thermo
Fisher Scientific). Eight micron frozen sections were cut,
collected on SuperFrost Plus slides (Thermo Fisher Sci-
entific) and stored at −20 °C until staining.
Fluorescence
Sections of NSV-GFP-infected tissues prelabeled with
DHE were imaged without further manipulation. Other
sections were brought to room temperature, washed in
PBS, and boiled for 20 min in 0.01 M citric acid in PBS
(pH 6.0) to unmask tissue antigens. Tissue sections were
then permeabilized for 5 min in 0.1 % Triton X-100 in
PBS and blocked for 30 min in 5 % normal goat serum
(NGS). Sections from NSV-infected CX3CR1GFP/+ mice
were incubated for 1 h at room temperature with poly-
clonal rabbit anti-AT1R (1:100, Santa Cruz Biotechnol-
ogy), washed three times in PBS, incubated with
rhodamine-conjugated goat anti-rabbit secondary anti-
body (1:200, eBioscience, San Diego, CA) for 1 h at
room temperature, and washed again prior to coverslip-
ping with Fluoromount G (eBiosciences) and imaging.
Neuronal damage in the brain was assessed in sections
prepared through the hippocampal formations of naïve
and NSV-infected C57BL/6 mice. Before staining, each
section was incubated in 0.1 % Triton X-100 for 15 min
to expose intracellular antigens. Slides were then stained
in 0.0001 % Fluoro-Jade C compound (EMD Millipore)
in 1 % acetic acid for 10 min. After further washing,
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slides were dried, counterstained with hematoxylin,
dehydrated in xylene, and coverslipped using Vecta-
Mount permanent mounting media (Vector Laborator-
ies, Burlingame, CA). Fluorescence was imaged using a
Nikon Ti-U inverted microscope equipped with a Cool-
SNAP EZ CCD digital camera (Photometrics, Tucson,
AZ) supported by the NIS-Elements Basic Research ac-
quisition and analysis software package (Nikon Instru-
ments Inc., Melville, NY). To quantify neuronal damage,
Fluoro-Jade C-positive cells (degenerating neurons) and
hematoxylin-positive cells (all neurons) were counted on
duplicate slides from each hippocampus of triplicate
mice for each experimental condition to calculate the
proportion of Fluoro-Jade-positive neurons.
Immunoperoxidase staining
For immunoperoxidase staining, permeabilized sections
were first treated with 1 % hydrogen peroxide in methanol
to block endogenous tissue peroxidase, and then blocked
in 2 % NGS. Slides were washed, incubated with polyclonal
rabbit anti-4-hydroxynonenal (4-HNE, 1:250, Abcam) for
1 h at room temperature, washed again, and then treated
with biotin-labeled goat anti-rabbit IgG (Vector
Laboratories) at a 1:200 dilution for another hour at room
temperature. These steps were followed by sequential incu-
bations with avidin-DH-biotin complex (Vector Laborator-
ies) and then 0.5 mg/ml 3,3′-diaminobenzidine (Sigma-
Aldrich) in PBS containing 0.01 % hydrogen peroxide. All
slides were counterstained with hematoxylin and mounted
with coverslips using Permount mounting medium
(Thermo Fisher Scientific) for light microscopy. Slides were
imaged using a Nikon Ti-U inverted microscope equipped
with a Nikon DS-Fi-1 digital camera and supported by the
NIS-Elements Basic Research acquisition and analysis soft-
ware package (Nikon Instruments Inc.).
Silver staining
Neuronal damage in the spinal cord during NSV in-
fection was assessed by quantifying the axonal pro-
cesses of lumbar ventral spinal nerve roots as these
all originate from motor neurons in the lumbar spinal
cord that innervate the hind limb musculature. These
assays were conducted according to our published
methods [36]. In brief, sections of the entire lumbar
spinal column at the L4–L5 level were first decalci-
fied (Immunocal, Decal Corporation, Tallman, NY)
Fig. 1 Ang II levels increase in both the brains (a) and spinal cords (b) of mice with NSV encephalomyelitis, while treatment of NSV-infected mice
with the ACE inhibitor, captopril, suppresses Ang II induction in the CNS (c) and enhances disease survival (d). Tissue Ang II levels were measured
by EIA in homogenates collected from uninfected (day 0) or NSV-infected animals and normalized to the total extracted protein content of each
sample. Values measured in individual mice (n = 4–6 samples per time point) and mean concentrations at each time point are shown. One-way
ANOVA confirmed that Ang II levels change significantly in both CNS tissue compartments over time (p = 0.0005 for brain, p = 0.0132 for spinal
cord). Treatment of mice with captopril (10 mg/kg/day) suppressed Ang II induction on day 3 post-infection compared to mice given a vehicle
control (n = 5 samples per group, *p < 0.05 by Student’s t test). This same treatment regimen enhanced overall disease survival compared to mice
given a vehicle control (n = 7 mice per group, p = 0.002 using a log-rank (Mantel-Cox) test)
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and embedded in paraffin. Sections were then stained
using a modified Bielchowsky silver staining method
to label neurofilament proteins in each nerve axon, as
described [36]. Slides were imaged using a Nikon Ti-
U inverted microscope equipped with a Nikon DS-Fi-
1 digital camera and supported by the NIS-Elements
Basic Research acquisition and analysis software pack-
age (Nikon Instruments Inc.). Axonal density (the
number of intact axons per cross-sectional area of
each nerve root) was determined for the right and left
L4 and L5 ventral nerve roots from a minimum of
four animals in each experimental group.
Flow cytometry-based analysis and separation of CNS
myeloid cell subsets
Six days after NSV challenge, ten anesthetized C57BL/6
mice underwent transcardiac perfusion with chilled PBS. A
parallel cohort of five mice were infected and also treated
with 100 mg/kg/day of telmisartan for 6 days followed by
transcardiac perfusion. Brains and spinal cords were col-
lected from each mouse and homogenized into small frag-
ments. Tissue was suspended in Hank’s balanced salt
solution (HBSS) containing 28 U/ml DNase (Sigma-Al-
drich) for 30 min at 37 °C. Infiltrating mononuclear cells
(MNC) were isolated from tissue digests of five
Fig. 2 AT1R levels progressively increase in both the brains (a) and spinal cords (b) of mice with NSV encephalomyelitis; receptor expression remains
restricted to microglia (c) and infiltrating monocytes (d) in infected mice and receptor deletion confers significant protection against lethal disease (e).
Normalized AT1R expression in whole tissue extracts (n = 5 samples per time point) was determined by Western blot. One-way ANOVA confirmed that
AT1R levels changed significantly in both CNS compartments over time (p < 0.0001 for both brain and spinal cord). Using transgenic mice selectively
expressing GFP in CX3CR1+ cells, AT1R expression was found on a subset of microglia from the hippocampal formations of uninfected animals (c).
AT1R staining was not detected on any CX3CR1− cells. Bar= 20 μm. At peak inflammation (day 6), CD45low/CD11b + microglia and CD45high/CD11b +
infiltrating monocytes expressed equivalent levels of agtr1a mRNA (n = 5 samples per group) (d). Finally, global AT1R KO mice survived NSV infection
more readily than WT controls (n = 7 mice per group, p = 0.0148 using a log-rank (Mantel-Cox) test) (e)
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telmisartan-treated and five untreated mice by centrifuga-
tion over 30 %/70 % Percoll gradients (GE Healthcare Life
Sciences), counted, washed extensively with PBS containing
2 % fetal bovine serum (FBS), and stained with fluorescently
conjugated anti-CD45, anti-CD11b, anti-Ly6C, anti-
Ly6G, and anti-CD11c antibodies for myeloid cell
phenotyping, as well as anti-CD40 and anti-CD86 to
assess myeloid cell activation (all from eBiosciences).
The following staining patterns defined each myeloid cell
subset: CD45low/CD11b + (microglia), CD45high/CD11b
+/CD11c-/Ly6C+/Ly6G- (macrophages), CD45high/CD11b
+/CD11c-/Ly6C-/Ly6G- (monocytes), CD45high/CD11b
+/CD11c-/Ly6C-/Ly6G+ (neutrophils), and CD45high/
CD11b+/CD11c + (dendritic cells). In the remaining five
NSV-infected mice, CNS mononuclear cells were
pooled and the endogenous and recruited myeloid cell
subsets were physically separated from one another
into CD45low/CD11b + (microglia) and CD45high/CD11b
+ (all infiltrating myeloid cells) populations using a BD
FACSAria high-speed cell sorter (BD Biosciences, San
Jose, CA). Cells were stored in PrepProtect RNA
stabilization solution (Miltenyi Biotec, Auburn, CA) at
−20 °C until RNA isolation could be performed.
Quantitative PCR determination of agtr1a expression in
CNS myeloid cell subsets
Flow sorted cell subsets were thawed, pelleted, and care-
fully removed from the PrepProtect solution. Total RNA
was isolated from each cell population and cDNA gener-
ated using a high-capacity cDNA reverse transcription kit
according to the manufacturer’s instructions (Thermo
Fig. 3 Telmisartan protects mice against both moderate or severe
hind limb paralysis (a) and death (b) following NSV challenge in a
dose-dependent manner. Cohorts of animals (n = 15–23 mice per
group) were inoculated with NSV and treated twice daily with either
telmisartan or a vehicle control at the daily doses indicated. Blinded
examiners scored each animal daily as described. The proportion of
mice in each group that remained either normal/mildly affected (a) or
alive (b) was calculated over time. Statistical differences between drug-
treated groups and vehicle-treated controls were determined using a
log-rank (Mantel-Cox) test. Individual p values are as follows: *p< 0.0001;
**p= 0.0002; ***p= 0.0244; †p< 0.0001; ††p= 0.0148; †††p= 0.1514
Fig. 4 Telmisartan has no effect on the replication or clearance of NSV
from the brains (a) or spinal cords (b) of NSV-infected animals. Mice were
inoculated with NSV and treated with telmisartan (100 mg/kg/day) or a
vehicle control. Replicate mice were sacrificed at predetermined intervals,
and viral titers were measured in each tissue sample by plaque titration
assay. Mean ± SEM of the log10 of tissue plaque-forming units (pfu) per
gram of tissue are shown. Two-way ANOVA confirmed that the virus
replication curves from vehicle- and telmisartan-treated mice are not
different from each other (p= 0.74 for brain, p= 0.31 for spinal cord)
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Fisher Scientific). Quantitative PCR (qPCR) was per-
formed to measure agtr1a and β-actin mRNA transcripts
using the MyiQ Single Color Real-Time PCR Detection
System and a Bio-Rad iQ5 cycler (Bio-Rad, Hercules, CA).
TaqMan® gene expression assays for both agtr1a and β-
actin were obtained from Thermo Fisher Scientific. Levels
of agtr1a transcripts were calculated relative to β-actin
using the following formula: 2^[Ct (β-actin) −Ct (target
gene)] × 1000, where Ct is the threshold cycle at which the
fluorescent signal became significantly higher than back-
ground. Results presented reflect relative agtr1a mRNA
expression in each cell population done in three experi-
mental replicates.
Tissue viral titrations
To measure the amount of infectious virus present in
CNS tissues, animals were perfused extensively with
chilled PBS and brains and spinal cords were extracted,
weighed, snap-frozen on dry ice, and stored at −80 °C
until virus titrations assays were performed. At that time,
20 % (w/v) homogenates of each sample were prepared in
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich), and serial tenfold dilutions of each homogenate
were assayed for plaque formation on monolayers of
BHK-21 cells. Results presented are the mean ± SEM of
the log10 of viral pfu per gram of tissue derived from a
minimum of three animals at each time point.
Measurement of tissue superoxide-generating activity
The capacity of CNS tissues to generate ROS was mea-
sured directly ex vivo using the well-established cyto-
chrome c reduction assay on fresh tissue membrane
extracts, as described [37, 38]. Briefly, animals were per-
fused with chilled PBS, and brains and spinal cords were
extracted, weighed, and homogenized to a final concen-
tration of 1 mg/ml total tissue protein in DMEM. One
hundred-eighty microliters of each homogenate was
then added to 96-well, flat-bottom plates in duplicate.
Purified superoxide dismutase (SOD, Sigma-Aldrich)
was then added to half the wells at a final concentration
of 200 U/ml, while DMEM was added to the remaining
wells as a control. All wells then received 500 μmol/l
Fig. 5 Telmisartan has no effect on the local CNS inflammatory response induced following NSV infection. At peak inflammation (day 6), total MNC
infiltration was not suppressed in either the brains or spinal cords of mice (n = 5 mice per group) treated with telmisartan (100 mg/kg/day) compared
to a vehicle control (a). By flow cytometry, the proportions of different brain-infiltrating myeloid cell subsets (CD45+/CD11b+) were not different
between these two groups (b). Likewise, expression of CD40 (c) and CD86 (d) were not changed on any resident or CNS-infiltrating myeloid cell subset
in the setting of drug treatment as assessed by the mean fluorescence intensity (MFI) of staining for the two activation markers
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purified cytochrome c (Sigma-Aldrich) and 100 μmol/l
purified NADPH (Sigma-Aldrich) as a specific electron
donor, and plates were incubated at 37 °C for 30 min.
Immediately thereafter, the absorbance of each well was
read at 540, 550, and 560 nm using a PowerWave HT
spectrophotometer (BioTek, Winooski, VT). Tissue O2
−
production by each sample was calculated by first sub-
tracting the average optical density (OD) readings at 540
and 560 nm from the average OD reading at 550 nm
(ΔOD). The difference in ΔOD value in the absence and
presence of SOD was then divided by the extinction co-
efficient of cytochrome c using the following formula:
(ΔOD without SOD – ΔOD with SOD)/21.1. Results are
presented as nmol O2
− produced/mg tissue protein.
Statistical comparisons
The Prism 5.0 software package (GraphPad Software,
La Jolla, CA) was used for all statistical analyses. Stu-
dent’s t test was applied when comparing a single
group under two experimental conditions, a one-way
analysis of variance (ANOVA) with a post hoc Bon-
ferroni’s multiple comparison test was used to investi-
gate the significance of a single group’s change over
time, while a two-way ANOVA with a post hoc Bon-
ferroni’s multiple comparison test was utilized to
compare experimental findings between two groups
over time. Differences in outcome among individual
cohorts of infected mice were determined using a
log-rank (Mantel-Cox) test. In all cases, differences at
a p < 0.05 level were considered significant.
Results
Role of the Ang II-AT1R axis in the CNS during NSV
encephalomyelitis
To explore whether Ang II-AT1R signaling influences dis-
ease outcome in mice with NSV encephalomyelitis, we
measured Ang II concentrations directly in CNS tissues
over time. These assays showed that Ang II levels in-
creased in both the brains and spinal cords of mice over
the first few days following NSV infection (Fig. 1a, b). Fur-
thermore, local Ang II production was suppressed via sys-
temic administration of captopril (Fig. 1c), an angiotensin
converting enzyme (ACE) inhibitor that prevents Ang II
cleavage from its precursor, angiotensinogen (AGT).
Importantly, mice treated with this drug showed en-
hanced survival compared to animals receiving a ve-
hicle control (Fig. 1d). These data suggest that local
Ang II production could be an important early event
that triggers CNS damage and leads to fatal disease
in mice with NSV infection.
We next characterized CNS AT1R expression, demon-
strating that tissue receptor levels increased steadily in both
the brains and spinal cords of NSV-infected animals (Fig. 2a,
b). A representative Western blot is shown (Additional file
1: Figure S1). Using CX3CR1GFP/+ mice with constitutively
green microglia [39], AT1R expression was identified by
histochemical staining on a subset of these cells in the
brains of naïve animals (Fig. 2c). Because CX3CR1-positive
cells could also represent GFP-positive monocytes in-
filtrating from the periphery [39], these two cell popula-
tions were separated from the brains of NSV-infected
animals by flow sorting for ex vivo analysis. Using this
Fig. 6 Telmisartan has no effect on the systemic or local CNS production of myeloid-related immune factors following NSV challenge. At peak
inflammation (day 6), plasma and brain tissue was collected from mice (n = 5 mice per group) treated with telmisartan (100 mg/kg/day)
compared to a vehicle control. Plasma samples were assayed without further manipulation. Tissue homogenates were first normalized to the total
extracted protein content of each sample. Plasma and brain levels of myeloid-related immune factors were measured using a commercial assay
according to the manufacturer’s instructions. Plasma (pg/ml) or brain (pg/mg total tissue protein) concentrations are shown. No differences in
any vehicle- versus telmisartan-treated brain concentrations were identified
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approach, anti-AT1R antibodies proved unreliable to de-
tect surface expression by flow cytometry, but agtr1a tran-
scripts were found at equivalent levels in CD45low/CD11b
+ microglia and CD45high/CD11b + infiltrating myeloid
cells at peak disease (Fig. 2d). No AT1R expression was
detected by histochemical staining on CX3CR1-negative
cells in either control or NSV-infected tissues (Fig. 2c and
data not shown). Finally, AT1R KO mice challenged with
NSV demonstrated improved survival compared to wild-
type (WT) controls (Fig. 2e). These results confirm that
AT1R signaling contributes to NSV pathogenesis. Further-
more, local pharmacological blockade of AT1R in the
CNS, if achieved, would act mainly on the endogenous
and recruited myeloid cell populations in this disease
setting.
Effects of a systemically administered AT1R antagonist on
the course of lethal alphavirus encephalomyelitis in mice
We next investigated the effects of telmisartan on the
course of NSV encephalomyelitis, a drug known to effect-
ively penetrate the BBB and cause sustained AT1R blockade
without affecting AT2R signaling [28]. Cohorts of mice
were treated twice daily with the drug beginning 12 h after
viral challenge. Escalating doses up to 100 mg/kg/day were
used, below those previously shown to lower systemic
arterial blood pressure in rodents [40]. Analyses of
disease outcomes in these cohorts showed that drug
treatment attenuated the development of severe hind
limb paralysis and prevented death in a dose-
dependent manner compared to animals given a ve-
hicle control (Fig. 3). These data further support a
role for AT1R signaling in NSV pathogenesis.
Virus titrations were performed on tissues derived from
vehicle- and telmisartan-treated animals to investigate
whether the drug had any effect on CNS virus replication
or spread. These assays showed that virus replication was
completely unaltered in both the brains and spinal cords of
NSV-infected mice treated with the highest protective dose
of telmisartan examined (Fig. 4). Furthermore, infection
with NSV-GFP demonstrated that drug treatment did not
change virus tropism for neurons or reduce the number of
infected cells in heavily targeted CNS regions such as the
hippocampus or the lumbar spinal cord (data not shown).
These results show that telmisartan produces benefits in
mice with NSV encephalomyelitis through a mechanism
other than one involving direct antiviral activity.
To investigate whether telmisartan exerted any anti-
inflammatory effects in NSV-infected animals, we
measured total MNC infiltration into the CNS, the re-
cruitment of individual myeloid cell subsets into the
brain, the cellular activation status of these CNS myeloid
cells, and circulating and CNS levels of myeloid cell-
related immune factors after 6 days of treatment. Ex vivo
analyses of CNS isolates from infected animals showed
that total tissue MNC were not reduced in telmisartan-
compared to vehicle-treated mice (Fig. 5a). The propor-
tions of five distinct myeloid cell subsets were equivalent
between the two groups (Fig. 5b), and telmisartan had
no effect on expression levels of the activation markers,
CD40 and CD86, on any of these cell types (Fig. 5c, d).
When a panel of myeloid factors was measured in both
plasma and brain tissue from NSV-infected animals, tel-
misartan had minimal effects on the production of any
of these mediators in either tissue compartment (Fig. 6).
We conclude that telmisartan does not exert a global
anti-inflammatory effect in either the periphery or the
CNS during NSV infection.
To determine the broader relevance of telmisartan as a
treatment for alphavirus encephalitis, separate cohorts of
mice were challenged with the known human pathogen,
WEEV. Much like what was observed in NSV-infected
Fig. 7 Mice treated with telmisartan developed milder disease (a)
and were protected from death (b) following challenge with the
human alphavirus, WEEV. Mice were inoculated with WEEV and
treated with either telmisartan (100 mg/kg/day) or a vehicle control.
Blinded examiners scored each animal daily for both disease severity
and survival. The mean ± SEM disease score (a) and the proportion
of animals surviving (b) are shown (n = 8 mice/group). A two-way
ANOVA confirmed that drug treatment lessened disease severity
(p < 0.0001), while a log-rank (Mantel-Cox) test confirmed that
telmisartan enhanced disease survival (p = 0.0139)
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animals, systemic administration of telmisartan at a
similar dose caused reduced disease severity in WEEV-
infected mice compared to vehicle-treated controls
(Fig. 7a). Half of the treated animals survived infection
compared to what was uniformly lethal without the drug
(Fig. 7b). These data confirm that telmisartan can pro-
tect a significant proportion of mice using a lethal chal-
lenge model of a clinically relevant alphavirus. As ARB
drugs are in widespread human use, and as antiviral
drugs effective against the alphaviruses still remain a
long way from human application [41, 42], blockade of
this signaling pathway might be considered for testing in
both equine and human cases of acute alphavirus
encephalitis.
Effects of telmisartan on Nox activation, ROS production,
and oxidative neuronal injury in the CNS during NSV
encephalomyelitis
Given the known capacity of ARBs to suppress Nox-
mediated ROS production in both vascular smooth
muscle and renal podocytes [22, 23, 29], we next sought
to determine whether telmisartan suppresses tissue ROS
production and oxidative neuronal injury as a potential
mechanism through which it protected NSV-infected ani-
mals. To investigate Nox activity in the CNS during dis-
ease, tissue subunit expression and tissue enzyme activity
were measured ex vivo. Via Western blot, multiple Nox
subunits were induced in both the brains and spinal cords
of NSV-infected animals over time (Fig. 8a, b). A repre-
sentative blot is shown (Additional file 2: Figure S2). Using
an established method to quantify superoxide production
in tissue extracts via ex vivo reduction of cytochrome c
and exogenous NADPH as an electron donor [37, 38], we
found clear biochemical evidence that enzymes capable of
generating ROS were induced in both the brains and
spinal cords of animals 72 h following NSV challenge
(Fig. 8c, d). Furthermore, this enzyme activity was potently
suppressed in tissues derived from infected mice treated
with telmisartan, and it was ablated in samples collected
from infected gp91/p47 DKO animals not treated with the
drug (Fig. 8c, d). On the other hand, telmisartan had no
effect on the induction of Nox subunits in the CNS by
Western blot (data not shown). We conclude that Nox is
the principal enzymatic source of tissue ROS in this
Fig. 8 Nox subunits are upregulated in the CNS following NSV challenge (a, b), and enzymatic activity capable of generating ROS is both
induced in the brains (c) and spinal cords (d) of infected animals and inhibited by telmisartan as well as by genetic deletion of Nox subunits.
Normalized gp91 and p47 expression in whole tissue extracts was determined by Western blot as described in the “Methods” section. One-way
ANOVA confirmed that levels of both Nox subunits changed significantly in both CNS regions over time (p < 0.0001). ROS-generating enzyme
activity was measured directly in tissue extracts as described in the “Methods” section. Values derived from individual mice as well as mean
enzyme activity levels are shown for each experimental condition (n = 5 mice/group). Student’s t test was used to analyze the degree to which
telmisartan (100 mg/kg/day) or Nox subunit deletion suppressed enzyme activity in tissues derived from NSV-infected animals compared to those
from vehicle-treated controls (*p = 0.0009 in brain and p = 0.0026 in spinal cord; **p = 0.0005 in brain and p = 0.0004 in spinal cord)
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disease setting, and that telmisartan suppresses Nox activ-
ity in the CNS without inhibiting expression of the en-
zyme complex itself.
To investigate the spatial expression of ROS directly in
CNS tissues, animals were infused with DHE immedi-
ately prior to sacrifice. This cell-permeable dye gets oxi-
dized to the fluorescent compound, ethidium, by
intracellular ROS and trapped within cells [43]. We
found that DHE labeling was increased in the spinal
cord 96 h after viral challenge when compared to labeled
tissue derived from uninfected animals. This ROS signal
remained largely confined to gray matter regions where
infected cells were also found (Fig. 9a, b). Systemic treat-
ment with telmisartan at protective doses largely abol-
ished this DHE staining (Fig. 9c). Similar patterns of
DHE labeling suppressed by telmisartan treatment were
also observed in the brain, and no DHE labeling above
background was found in tissues from NSV-infected but
otherwise untreated gp91/p47 DKO mice (data not
shown). Since drug treatment did not inhibit virus repli-
cation in either the brain or spinal cord (Fig. 4), we con-
clude that ROS do not exert any antiviral effect during
alphavirus encephalitis.
ROS generated as part of an inflammatory response can
damage cellular lipids, proteins, and nucleic acids. A lipid
peroxidation product detectable in cell membranes, 4-
HNE, is both a validated marker for, as well as a direct
mediator of, oxidative injury to neurons [44, 45]. We
found that CNS tissues derived from NSV-infected ani-
mals showed prominent 4-HNE immunoreactivity in
spinal gray matter within 72 h of viral challenge compared
to uninfected controls (Fig. 10a, b). At higher magnifica-
tion, heavy labeling of neuronal cell bodies, with moderate
staining of gray matter neuropil, was observed (Fig. 10c).
Treatment with telmisartan visibly reduced 4-HNE stain-
ing observed in infected tissue samples (Fig. 10d). Similar
patterns of 4-HNE immunoreactivity were also identified
in the hippocampus (data not shown).
Based on this distribution of staining, the effects of tel-
misartan on the survival of hippocampal and lumbar ven-
tral spinal motor neurons were quantified following NSV
infection. Using Fluoro-Jade C labeling, an established
histochemical marker of irreversible neuronal injury [46],
damaged hippocampal neurons were easily identified on
day 7 post-infection compared to naïve controls (Fig. 11a),
and quantification of these cells showed that the drug
exerted a measurable neuroprotective effect compared to
vehicle-treated controls (Fig. 11b). Likewise, silver staining
of sections through the lumbar spinal columns of these
mice allowed the identification of lumbar ventral nerve
roots carrying axons from lumbar ventral motor neurons
(Fig. 11c); quantification of these axons showed that sur-
vival of these cells was also enhanced by telmisartan
(Fig. 11d). Together, these findings demonstrate that a
Fig. 9 In vivo labeling shows that ROS are induced in ventral gray
matter of the lumbar spinal cord (outlined) following NSV challenge
and that ROS induction is suppressed in infected animals treated
with telmisartan. ROS-containing cells (red) were labeled by injecting
mice with DHE just prior to sacrifice as described in the “Methods”
section. A GFP-expressing virus was used to identify NSV-infected
neurons (green). Negligible ROS staining was observed in uninfected
control animals (a). Four days after NSV challenge, ROS were
detected in relative proximity to, but not necessarily within, infected
neurons (b). Telmisartan administration (100 mg/kg/day) abolished
nearly all ROS labeling in infected animals at this time point (c).
Calibration bar = 75 μm for all panels
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systemically administered ARB can penetrate the CNS to
inhibit Nox activity and local ROS production, thereby
limiting oxidative neuronal damage during NSV
encephalomyelitis.
Effects of Nox subunit deletion on telmisartan-mediated
protection during NSV encephalomyelitis in vivo
Although multiple enzymes could theoretically be generat-
ing ROS in the CNS following NSV infection, Nox ap-
pears to be their primary source given the results of both
our biochemical assays (Figs. 8c, d) as well as the absence
of DHE staining in infected gp91/p47 DKO mice (data not
shown). When gp91/p47 DKO mice were challenged with
NSV, these hosts survived infection significantly better
than WT controls (Fig. 12a). Furthermore, when telmisar-
tan was given to cohorts of NSV-infected gp91/p47 DKO
hosts, the survival benefit conferred by the drug was abol-
ished compared to DKO animals treated with a vehicle
control (Fig. 12b). These data confirm that Nox activity is
pathogenic during NSV infection, and that Nox is the
main therapeutic target of telmisartan in this alphavirus
encephalitis model.
Discussion
Although natural outbreaks of mosquito-borne enceph-
alitis caused by alphaviruses remain rare events, aerosol
transmissibility makes some of these pathogens potential
bioterrorism agents [1]. Other dangerous features of
alphaviruses include their potential to cause incapacitat-
ing disease, their relatively high infectivity for humans,
the ease with which they can be mass produced, and the
lack of effective countermeasures for disease prevention
or control [1]. Studies undertaken in murine alphavirus
encephalitis models have demonstrated that blocking
host responses arising from activated microglial cells can
protect infected hosts, often without suppressing CNS
virus replication or spread [7, 10–14]. Although the mo-
lecular pathways leading to neuronal damage in infected
mice are incompletely understood, strategies to subvert
these injurious host responses remain fertile areas of in-
vestigation. Here, we implicate a novel injury mechanism
in the CNS–ROS production via Nox activation—as an
important contributor to alphavirus pathogenesis. We
also demonstrate that an existing ARB capable of pene-
trating the BBB can effectively inhibit CNS Nox activ-
ity, prevent oxidative neuronal damage, and reduce
disease morbidity and mortality in diseased animals
without having any effect on local virus replication or
clearance. This raises questions as to whether these
drugs could have broader uses in the treatment of
neurologic disorders where oxidative injury is known
or hypothesized to occur.
Fig. 10 Telmisartan blocks oxidative changes to neurons in the spinal cords of NSV-infected mice. Immunohistochemical staining for 4-HNE, a
lipid peroxidation product that accumulates in cell membranes following ROS exposure, is induced 4 days after NSV infection (b) compared to
expression in uninfected control animals (a). Higher magnification views show prominent staining of neuronal cell membranes with less intense
labeling of neuropil in ventral gray matter of infected animals (c). Treatment of NSV-infected mice with telmisartan (100 mg/kg/day) for 4 days
blocks most of the observed 4-HNE immunoreactivity (d). Calibration bar = 250 μm in panels a, b and d; 20 μm in panel c
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Broadly defined, oxidative stress results from the in-
creased production of both ROS and reactive nitrogen
species (RNS) to an extent that cellular antioxidant de-
fenses get overwhelmed. Both acute infections caused by
herpes simplex virus and chronic infections caused by
human immunodeficiency virus and measles virus are
known to cause oxidative damage to neurons and glial
cells within the CNS [21]. On the other hand, the extent
to which the oxidative burst can benefit the infected
host by limiting virus replication is unknown. Further-
more, ROS are known to participate in normal intracel-
lular signaling, and Nox activation has now been shown
to facilitate cellular Toll-like receptor (TLR) responses
and augment type-1 interferon production following
engagement of the cytoplasmic viral sensor, retinoic
acid-inducible gene I (RIG-I) [47, 48]. Thus, local Nox
activation could in theory either positively or negatively
influence the outcome of CNS viral infection. We find
that systemic administration of the ARB, telmisartan,
potently suppresses Nox activity in both the brains and
spinal cords of mice with NSV encephalomyelitis, effect-
ively blocking local ROS production and preventing oxi-
dative neuronal injury without altering virus replication
or clearance. Evidence that the drug confers protection
through a Nox-dependent pathway and not via some
off-target effect comes from our observation that gp91/
p47 DKO mice that do not generate any oxidative burst
in the CNS following virus challenge, have improved
disease outcomes compared to WT controls, and are
completely unresponsive to telmisartan following NSV
infection. Taken together, our data show that Nox acti-
vation is pathogenic in this disease setting and that this
enzyme complex can be effectively targeted to benefit
the host via systemic administration of a compound
already widely used in humans.
While originally developed for use in treating hyperten-
sion and more recently shown to exert neuroprotective ef-
fects in stroke models [24–27], ARBs are now confirmed
to have benefits during experimental neuroinflammation.
In experimental autoimmune encephalomyelitis (EAE),
the principal mouse model of multiple sclerosis (MS), sys-
temically administered ARBs can suppress disease severity
[49–51]. One study showed that ARB treatment disrupted
local astrocyte and microglial production of the inflamma-
tory factor, transforming growth factor-beta (TGF-β), and
suppressed myeloid cell recruitment to the CNS [51]. The
authors of this study inferred that actions on these glial
cells were primary and that suppressed inflammatory cell
Fig. 11 Telmisartan prevents irreversible neuronal damage and loss in the brains and spinal cords of NSV-infected mice. Fluoro-Jade C staining
shows extensive labeling of hippocampal neurons in a mouse 7 days after NSV infection (right panel, a) compared to an uninfected control (left
panel, a). Bar = 75 μm for both panels. Quantification of staining at this stage of infection as described in the “Methods” section shows that
telmisartan (100 mg/kg/day) reduces damage to these neurons compared to animals treated with a vehicle control (b). In the lumbar spinal cord,
silver staining shows prominent axonal loss in individual ventral nerve roots (each marked with an *) on day 7 post-infection (right panel, c)
compared to an uninfected control (left panel, c). Bar = 100 μm for both panels. Quantification of axonal density in these ventral nerve roots as
described in the “Methods” section shows that telmisartan treatment (100 mg/kg/day) reduces damage to lumbar motor neurons from which
these axons arise compared to animals treated with a vehicle control (d). Student’s t test was used to analyze both the degree of cell damage in
vehicle-treated versus naïve mice (†p < 0.0001 in both the hippocampus and spinal cord) as well as the degree to which drug treatment
suppressed neuronal damage compared to those from vehicle-treated controls (*p = 0.0006 in the hippocampus; *p = 0.0005 in the spinal cord)
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infiltration into diseased CNS tissue was a secondary ef-
fect [51]. In a mouse model of traumatic brain injury, a
single dose of telmisartan given 6 h after injury caused re-
duced perilesional staining for CD68, ionized calcium
binding adaptor molecule 1 (Iba-1), and myeloperoxidase
(MPO) at 72 h, while a similar treatment 24 h after injury
had no such effect [52]. In this setting, however, the cells
targeted by telmisartan were not specifically identified,
and its effects proved largely dependent on peroxisome
proliferator-activated receptor gamma (PPARγ) agonism
as opposed to AT1R blockade [52]. Other in vitro studies
have also shown that the anti-inflammatory actions of
ARBs on myeloid cells correlate with their PPARγ agonist
potency [53]. Although our work does not specifically ad-
dress the role of PPARγ in NSV pathogenesis, we found
no evidence that telmisartan conferred benefit in the
setting of Nox deficiency or exerted a more global anti-
inflammatory effect. This variability in response might be
explained by its capacity to act on multiple targets in dif-
ferent disease models. Indeed, in some settings telmisartan
may directly enter target cells and scavenge intracellular
ROS fully independent of its AT1R blocking effects [54].
The renin-angiotensin system (RAS) has now been
recognized to exert direct actions within the CNS and to
serve roles beyond the neural control of cardiovascular
function [55, 56]. These observations have spawned
many studies to examine the cellular localization of RAS
components within the brain. There is some consensus,
for example, that AGT and the cleaving enzymes needed
for Ang II synthesis exist in distinct neural cell types
[55]; this would imply that a network of cells contributes
to the final production of this mediator. As for Ang II
receptors, most reports validate that both AT1R and
AT2R are found at varying levels throughout the brain,
although debate still rages surrounding their relative
localization to neurons versus glial cells [55, 56]. While
some genetic models suggest that Ang II receptors are
found primarily on neurons under steady state condi-
tions [57, 58], co-localization using glial-specific reporter
mice has not been described until now. Furthermore,
AT1R are found on peripheral immune cells [59] and
are abundant on CNS-infiltrating myeloid cells during
both EAE and MS [50]. Using CX3CR1GFP/+ mice that
label both microglia and peripheral monocytes [39],
histochemical staining of tissue sections as well as direct
physical separation of CNS myeloid cell subsets by flow
cytometry allowed us to confirm that AT1R localizes
principally to CX3CR1+ and to CD45+/CD11b+ cells
during NSV infection. Ongoing studies will use WT and
AT1R KO mice to create bone marrow chimeras in
order to confirm that hematopoietic cells are the main
target of telmisartan in this disease, with a longer-term
goal being the creation of a conditional AT1R KO
mouse. Nonetheless, our current findings fit with other
studies showing that aberrant host responses arising
from activated myeloid cells contribute to NSV patho-
genesis [7, 10, 13], even if they do not yet shed any light
on the source or mechanism of local Ang II production
following NSV infection.
Finally, it bears considering that another group recently
studied the role of Ang II and ARB signaling in a closely
related infection model caused by another alphavirus,
Venezuelan equine encephalitis virus (VEEV), in rats.
These investigators found that Ang II expression in-
creased rapidly in the CNS following VEEV infection, but
that daily treatment of animals with losartan (30 mg/kg)
actually accelerated death compared to rats given a vehicle
control [60]. In their hands, losartan suppressed VEEV-
mediated induction of the pro-inflammatory mediators,
IL-1α and CCL2, as well as the anti-inflammatory com-
pound, IL-10, but had no effect on IL-6 levels in the brain
Fig. 12 Nox-deficient mice are protected from NSV infection
compared to WT controls, while telmisartan has no protective effect in
Nox-deficient hosts. In the absence of any drug treatment, gp91/p47
DKO mice survived NSV infection much better than WT control animals
(a). When gp91/p47 DKO mice were treated with either telmisartan
(100 mg/kg/day) or a vehicle control, no survival difference between
the two groups was observed (b). Statistical differences in outcome
between these cohorts (n = 22 mice/group) were determined using a
log-rank (Mantel-Cox) test. Individual p values are shown
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[60]. Drug treatment also reduced vascular pathology in
the CNS of VEEV-infected animals, but had no quantita-
tive effects on cellular infiltration into the brain. They
concluded that Ang II-driven neuroinflammation could be
a host defense mechanism that limits virus damage and fa-
vors survival [60]. Unfortunately, however, their conclu-
sions contradict numerous other studies showing that
host responses actually drive VEEV pathogenesis and
directly contribute to mortality [61–63]. We otherwise re-
main unable to explain why our results differ so dramatic-
ally from these investigators’ conclusions using a related
encephalitis model.
Conclusions
Our data show that components of the RAS are induced
in the CNS during the early stages of alphavirus encephal-
itis, and that the ARB, telmisartan, acts in a highly
targeted manner to suppress Nox activity in both en-
dogenous and CNS-infiltrating myeloid cells and protect
infected hosts from lethal disease. Impaired ROS produc-
tion reduces neuronal injury, and the abrogation of clinical
protection in Nox-deficient hosts confirms that these en-
zymes are the main target of this drug in this setting.
Given widespread use in humans, this ARB may also con-
fer benefit in treating neurologic disorders where oxidative
injury is known or hypothesized to occur.
Additional files
Additional file 1: Figure S1. Representative Western blots show
induction of AT1R in both the brain and spinal cord over the course of
acute NSV infection relative to the expression of a β-actin loading control
in each tissue sample (TIF 352 KB). (TIF 297 kb)
Additional file 2: Figure S2. Representative Western blots show
induction of the Nox subunits, gp91 and p47, in both the brain and spinal
cord over the course of acute NSV infection relative to the expression of a
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